Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) Short Interest Down 39.1% in February

Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) saw a large decrease in short interest during the month of February. As of February 15th, there was short interest totalling 520,300 shares, a decrease of 39.1% from the January 31st total of 853,700 shares. Based on an average trading volume of 1,100,000 shares, the short-interest ratio is currently 0.5 days. Currently, 2.4% of the shares of the stock are sold short.

Institutional Trading of Inspira Technologies Oxy B.H.N.

An institutional investor recently raised its position in Inspira Technologies Oxy B.H.N. stock. Citadel Advisors LLC raised its holdings in Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) by 422.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 86,763 shares of the company’s stock after acquiring an additional 70,159 shares during the period. Citadel Advisors LLC owned approximately 0.69% of Inspira Technologies Oxy B.H.N. worth $88,000 at the end of the most recent quarter. 12.72% of the stock is owned by institutional investors and hedge funds.

Inspira Technologies Oxy B.H.N. Price Performance

IINN stock traded down $0.03 during mid-day trading on Tuesday, reaching $0.84. The company’s stock had a trading volume of 657,177 shares, compared to its average volume of 1,656,892. The company has a quick ratio of 2.13, a current ratio of 2.23 and a debt-to-equity ratio of 0.09. Inspira Technologies Oxy B.H.N. has a fifty-two week low of $0.77 and a fifty-two week high of $2.45. The company’s 50 day moving average is $0.96 and its two-hundred day moving average is $1.15.

Inspira Technologies Oxy B.H.N. Company Profile

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels.